142 related articles for article (PubMed ID: 28125821)
1. The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004).
Choudhury A; West CM; Porta N; Hall E; Denley H; Hendron C; Lewis R; Hussain SA; Huddart R; James N
Br J Cancer; 2017 Feb; 116(5):649-657. PubMed ID: 28125821
[TBL] [Abstract][Full Text] [Related]
2. Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial.
Hall E; Hussain SA; Porta N; Lewis R; Crundwell M; Jenkins P; Rawlings C; Tremlett J; Sreenivasan T; Wallace J; Syndikus I; Sheehan D; Lydon A; Huddart R; James N;
Eur Urol; 2022 Sep; 82(3):273-279. PubMed ID: 35577644
[TBL] [Abstract][Full Text] [Related]
3. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial.
Hussain SA; Porta N; Hall E; Salawu A; Lewis R; Sreenivasan T; Wallace J; Crundwell M; Jenkins P; Tremlett J; Huddart R; James ND;
Eur Urol; 2021 Feb; 79(2):307-315. PubMed ID: 33293079
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.
James ND; Hussain SA; Hall E; Jenkins P; Tremlett J; Rawlings C; Crundwell M; Sizer B; Sreenivasan T; Hendron C; Lewis R; Waters R; Huddart RA;
N Engl J Med; 2012 Apr; 366(16):1477-88. PubMed ID: 22512481
[TBL] [Abstract][Full Text] [Related]
5. Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004).
Huddart RA; Hall E; Hussain SA; Jenkins P; Rawlings C; Tremlett J; Crundwell M; Adab FA; Sheehan D; Syndikus I; Hendron C; Lewis R; Waters R; James ND
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):261-9. PubMed ID: 23958147
[TBL] [Abstract][Full Text] [Related]
6. Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy.
Korpics MC; Block AM; Martin B; Hentz C; Gaynor ER; Henry E; Harkenrider MM; Solanki AA
Cancer; 2017 Sep; 123(18):3524-3531. PubMed ID: 28581675
[TBL] [Abstract][Full Text] [Related]
7. A hypoxia biomarker does not predict benefit from giving chemotherapy with radiotherapy in the BC2001 randomised controlled trial.
Smith TAD; West CML; Joseph N; Lane B; Irlam-Jones J; More E; Mistry H; Reeves KJ; Song YP; Reardon M; Hoskin PJ; Hussain SA; Denley H; Hall E; Porta N; Huddart RA; James ND; Choudhury A
EBioMedicine; 2024 Mar; 101():105032. PubMed ID: 38387404
[TBL] [Abstract][Full Text] [Related]
8. Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer.
Hussain SA; Stocken DD; Peake DR; Glaholm JG; Zarkar A; Wallace DM; James ND
Br J Cancer; 2004 Jun; 90(11):2106-11. PubMed ID: 15150587
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
[TBL] [Abstract][Full Text] [Related]
10. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.
Gunderson LL; Winter KA; Ajani JA; Pedersen JE; Moughan J; Benson AB; Thomas CR; Mayer RJ; Haddock MG; Rich TA; Willett CG
J Clin Oncol; 2012 Dec; 30(35):4344-51. PubMed ID: 23150707
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial.
Huddart RA; Hall E; Lewis R; Porta N; Crundwell M; Jenkins PJ; Rawlings C; Tremlett J; Campani L; Hendron C; Hussain SA; James ND;
Eur Urol; 2020 Feb; 77(2):260-268. PubMed ID: 31843338
[TBL] [Abstract][Full Text] [Related]
12. Expression of hypoxia-inducible factor-1α predicts benefit from hypoxia modification in invasive bladder cancer.
Hunter BA; Eustace A; Irlam JJ; Valentine HR; Denley H; Oguejiofor KK; Swindell R; Hoskin PJ; Choudhury A; West CM
Br J Cancer; 2014 Jul; 111(3):437-43. PubMed ID: 24937673
[TBL] [Abstract][Full Text] [Related]
13. Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option.
Meulendijks D; Dewit L; Tomasoa NB; van Tinteren H; Beijnen JH; Schellens JH; Cats A
Br J Cancer; 2014 Oct; 111(9):1726-33. PubMed ID: 25167226
[TBL] [Abstract][Full Text] [Related]
14. Radiation with concurrent radiosensitizing capecitabine tablets and single-dose mitomycin-C for muscle-invasive bladder cancer: A convenient alternative to 5-fluorouracil.
Voskuilen CS; van de Kamp MW; Schuring N; Mertens LS; Noordzij A; Pos F; van Rhijn BWG; van der Heijden MS; Schaake EE
Radiother Oncol; 2020 Sep; 150():275-280. PubMed ID: 32768507
[TBL] [Abstract][Full Text] [Related]
15. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial.
Mitin T; Hunt D; Shipley WU; Kaufman DS; Uzzo R; Wu CL; Buyyounouski MK; Sandler H; Zietman AL
Lancet Oncol; 2013 Aug; 14(9):863-72. PubMed ID: 23823157
[TBL] [Abstract][Full Text] [Related]
16. Pre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer.
Joseph N; Dovedi SJ; Thompson C; Lyons J; Kennedy J; Elliott T; West CM; Choudhury A
Ann Oncol; 2016 Feb; 27(2):294-9. PubMed ID: 26578732
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of the effectiveness between long-term instillation of mitomycin C and short-term prophylaxis with MMC or bacille Calmette-Guérin. Study of patients with non-muscle-invasive urothelial cancer of the urinary bladder].
Isbarn H; Budäus L; Pichlmeier U; Conrad S; Huland H; Friedrich MG
Urologe A; 2008 May; 47(5):608-15. PubMed ID: 18317718
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of systemic chemotherapy and intra-arterial chemotherapy with/without radiotherapy for bladder preservation or as neo-adjuvant therapy in patients with muscle-invasive bladder cancer: a single-centre study of 163 patients.
Miyata Y; Nomata K; Ohba K; Matsuo T; Hayashi N; Sakamoto I; Uetani M; Sakai H
Eur J Surg Oncol; 2015 Mar; 41(3):361-7. PubMed ID: 25312685
[TBL] [Abstract][Full Text] [Related]
19. Cystectomy outcomes in patients who have failed Radiofrequency-induced Thermo-chemotherapeutic Effect Mitomycin-C (RITE-MMC) treatment for high-risk non-muscle invasive bladder cancer (HRNMIBC)-Does it complicate surgery and adversely impact oncological outcome?
Sri D; Lee HJ; El-Gemmal S; Backhouse C; Tay A; John B; Perry MJ; Ayres BE; Issa R
Urol Oncol; 2021 May; 39(5):300.e15-300.e20. PubMed ID: 33032922
[TBL] [Abstract][Full Text] [Related]
20. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
